RFK Jr. Orders Review of Abortion Pill

The reversal of Roe v. Wade was a triumph for the pro-life movement, but the abortion industry didn’t retreat—it doubled down, aggressively marketing the abortion pill called mifepristone, as its new cash cow.

Mifepristone, marketed as a convenient and private way for women to end pregnancies at home, has significantly increased in use, often with little regard for the physical and emotional toll it takes on women.

And now, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is stepping up to protect American women by ordering a long-overdue review of this dangerous drug to ensure it’s not doing more harm than good.

Speaking before the Senate Health, Education, Labor and Pensions Committee, Kennedy had a strong urgency about the issue: “I requested Marty Makary, who just happens to be director of the FDA, to review in detail and to report back,” he said in citing an eye-opening report documenting the dangers of mifepristone.

For too long, the abortion industry has sold the pill as a safe, empowering option, hiding the startling truth about the devastating consequences—excessive bleeding, infections, and profound psychological trauma—that countless women have endured. Thus making Kennedy’s review a bold, pro-woman move to prioritize the health and well-being of those who’ve been misled by an industry more concerned with making a buck over its human impact.

Abortion Pills: the Pro-Abortion Workaround

The rise of the abortion pill has been a deliberate work-around by an industry which has intentionally sought to bypass pro-life laws.

In those states that have closed abortion facilities through policies affirming life, mifepristone is exported with minimal control, leaving women to continue alone, typically in misery. All too common are women’s stories of suffering quietly—body wracked with agony or conscience distorted with regret—only to be ignored by the abortion lobby, telling a tale of “choice” without concern for the real harm.

The FDA’s original mifepristone approval was hasty and grossly understudied and has been fought in court ever since it appeared, and deservedly so.

Kennedy’s call for scrutiny could finally expose the truth about a drug that’s been falsely sold as safe.

Far from placing any kind of “restriction” on women, this review is a lifeline for those who deserve better than the abortion industry’s callous disregard. It’s about ensuring women have access to accurate information, not just a pill that could leave them physically or emotionally broken.

Pro-abortion activists may cry foul, but their rhetoric can’t erase the stories of women who’ve suffered complications or been left to grapple with the aftermath alone.

Kennedy’s review is a chance to put women first—demanding rigorous science, transparency, and accountability from a drug that’s been shielded by politics for too long.

As the FDA digs in, American women can take heart: someone at the helm of America’s health policy is finally looking out for their health, their safety, and their future in a post-Roe world.

Thank you for your support.

If you appreciate the work we do to spread the good news of Jesus Christ, please consider giving a gift to help us continue this work. Maranatha!